Understand the source comparison
VIP for Men: Research Applications Comparison
Erectile Dysfunction VPAC2 receptor activation in corpus cavernosum smooth muscle → cAMP elevation → PKA-mediated vasodilation independent of NO pathway Phase 2 trials completed (1990s–2000s); intracavernosal injection formulations studied; limited commercial
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Erectile Dysfunction
- VPAC2 receptor activation in corpus cavernosum smooth muscle → cAMP elevation → PKA-mediated vasodilation independent of NO pathway
- Phase 2 trials completed (1990s–2000s); intracavernosal injection formulations studied; limited commercial development post-PDE5 inhibitor approval
- Rapid degradation (1–2 min half-life) requires local administration; systemic delivery ineffective; patient preference for oral alternatives
- Mechanistically sound but commercially unviable; research-grade protocols valid for comparative vasodilator studies
- Pulmonary Arterial Hypertension
- VPAC receptor-mediated pulmonary vasodilation + anti-proliferative effects on pulmonary artery smooth muscle cells
- Preclinical models show efficacy; inhaled VIP analogs studied in Phase 1 trials; no approved therapies yet
- Short half-life necessitates continuous infusion or depot formulations; analogs (e.g., aviptadil) under investigation for improved stability
- Strong preclinical rationale; clinical development ongoing but not yet definitive
- Autoimmune Modulation
- Suppression of IL-12/TNF-alpha, upregulation of IL-10/TGF-beta in dendritic cells and macrophages → regulatory T-cell expansion
- Efficacy demonstrated in EAE (MS model), collagen-induced arthritis, and IBD models in rodents; limited human trials
- Systemic delivery challenges due to rapid degradation; requires parenteral administration; no oral bioavailability
- Promising immunoregulatory profile in preclinical work; human translation limited by delivery constraints
- Neuroprotection & Neurodegeneration
- Intranasal delivery crosses BBB → reduces microglial activation, promotes amyloid-beta clearance, enhances synaptic plasticity via cAMP/CREB pathway
- Early-stage research in Alzheimer's and Parkinson's models; intranasal VIP reduced cognitive decline in APP/PS1 transgenic mice
- Human data sparse; dosing and delivery optimization required; mechanism not fully elucidated
- Mechanistic plausibility high; intranasal route bypasses degradation; requires Phase 1 safety data before broader application